Journal Mobile Options
Table of Contents
Vol. 29, No. 5, 2011
Issue release date: November 2011

Historical Impact to Drive Research in Peptic Ulcer Disease

Banić M. · Malfertheiner P. · Babić Z. · Ostojić R. · Kujundzic M. · Fatović-Ferenčić S. · Plesko S. · Petričušić L.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The story of gastric acid secretion began with early ideas on gastric secretion (Spallanzani and de Réaumur, 17th century) and with first descriptions of food digestion (Dupuytren and Bichat, Beaumont, early 18th century), followed by proof that gastric juice contained acid (Prout, early 18th century). The research continued with first descriptions of gastric glands as the source of gastric acid and its changes upon digestive stimulus (Purkinje and Golgi, mid and late 19th century). The theory of ‘nervism’ – the neuro-reflex stimulation of gastric secretion by vagal nerve (Pavlov, early 20th century) was contrasted by a histamine-mediated concept of gastric secretion (Popielski and Code, mid 20th century). Thus, gastric acid and pepsin (Schwann, early 19th century) were found to be essential for food digestion and studies also pointed to histamine, being the most potent final common chemostimulator of oxyntic cells. The discoveries in etiopathogenesis of mucosal injury were marked by the famous dictum: ‘No acid, no ulcer’ (‘Ohne saueren Magensaft kein peptisches Geschwür’, Schwarz, 1910) that later induced the term of ‘mucosal defense’ and the notion that the breaking of ‘gastric mucosal barrier’ represents the initial step in the process of mucosal injury (Davenport, Code and Scholer, mid 20th century). The prostaglandins were shown to influence all major components of gastric mucosal barrier, described with the term ‘cytoprotection’ (Vane, Robert and Jacobson, 1970s). Beginning in the latter half of 19th century, the studies on gastric bacteriology that followed enabled the discovery of association between Campylobacter (Helicobacter) pylori and peptic ulcers (Warren and Marshall, 1980s) that led to worldwide major interventions in treating peptic ulcer disease. The surgical approach to peptic ulcer had been outlined by resection procedures (Billroth, Pean, Moynihan, late 19 century) and vagotomy, with or without drainage procedures (Jaboulay, Latarjet, Dragstedt, mid 20th century). Antacids, protective agents, anticholinergics, and later gastrin antagonists and prostaglandins were used for decades in the treatment of peptic ulcer, with differing effects. The advent of the concept of H2-receptor antagonists (Black, 1970s) and the discovery of acid (proton) pumps in parietal cells (Ganser, Forte and Sachs, late 1970s) paved the way for potent (H2 antagonists) and profound acid inhibition (proton pump inhibitors) that revolutionized the treatment of acid-related disorders, including peptic ulcer disease. Worldwide, peptic ulcer and its complications remain the cause of significant morbidity, especially in older age groups, representing a major burden for ambulatory and hospital healthcare resources.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Hippocrates. The Genuine Works of Hippocrates. Translated by F. Adams. London, Sydenham Society, 1899, pp 166–161.
  2. Modlin IM, Sachs G: Acid-Related Diseases. Biology and Treatment. Constance, Schnetztor, 1998, pp 3–4.
  3. Vesalius A: De Humani Corporis Fabrica Libri Septem. Basel 1543.
  4. Spallanzani L: Dissertations Relative to the Natural History of Animals and Vegetables. Translated from the Italian of the Abbe Spallanzani. London, J. Murray, 1784, vol 1.
  5. De Réaumur RAF: Sur la digestion des oiseaux. Seconde mémoire. De la manière dont elle fait dans l’estomac des oiseaux de proie. Paris, Mem Acad Roy Sci, 1752, pp 461–495.
  6. Prout W: On the nature of the acid and saline matters usually existing in stomachs of animals. Philos Trans R Soc Lond 1824;114:45–49.

    External Resources

  7. Beaumont W: Experiments and observations on the gastric juice and the physiology of digestion. Fascimile of original 1833 edition. Oxford, Oxford Historical Books, 1989.
  8. Golgi C: Sur la fine organisation des glandes peptiques des mammifères. Arch Ital Biol 1893;19:448–453.
  9. Dalton AJ, Kahler H, Lloyd BJ: The structure of the free surface of a series of epithelial cell types in the mouse as revealed by the electron microscope. Anat Rec 1951:111:67–77.
  10. Pavlov IP: The Work of the Digestive Glands. London, Charles Griffin, 1902.
  11. Popielski L: β-Imidazolylaethylamin und die Organextrakte. Pflügers Arch Ges Physiol 1920;178:237–259.
  12. Code CF: Histamine and gastric secretion; in Wostenholme G, O’Connor C (eds): New York, Little Brown, 1956, pp 189–219.
  13. Edkins JS: The chemical mechanism of gastric secretion. J Physiol 1906;34:183.
  14. Gregory R, Tracy H: Constitution and properties of two gastrins extracted from hog antral mucosa. Gut 1964;5:103–105.
  15. Olbe L: Potentiation of sham feeding response in Pavlov pouch dogs by subthreshold amounts of gastrin with and without of acidification of denervated antrum. Acta Physiol Scand 1964;61:244–254.
  16. Schwann T: Über das Wesen des Verdauungsprozess. Arch Anat Physiolwiss 1836;90–138.
  17. Langley JN, Edkins JS: Pepsinogen and pepsin. J Physiol 1886;7:371–415.
  18. Heidenhain RP: Über die Pepsinbildung in den Pylorusdrüsen. Pflügers Arch Ges Physiol 1878;18:169–171.

    External Resources

  19. Card WI, Marks IN: The relationship between acid output of the stomach following ‘maximal’ histamine stimulation and parietal cell mass. Clin Sci 1960;19:147.
  20. Modlin IM, Sachs G: Acid-Related Diseases. Biology and Treatment. Constance, Schnetztor, 1998, pp 50–52.
  21. Black JW, Duncan VAM, Durant CJ, Ganellin CR, Parsons EM: Definition and antagonism of histamine H2 receptors. Nature 1972;236:385–390.
  22. Lloyd KC, Soll AH: Multiple pathways controlling acid secretion. J Gastroenterol 1994;29:77–79.
  23. Ganser AL, Forte JG: K+-stimulated ATPase in purified microsomes of bullfrog oxyntic cells. Biochem Biophys Acta 1973;307:169–180.
  24. Sachs G, Hershey SJ: The Gastric Parietal Cell. Its Clinical Relevance in the Management of Acid-Related Diseases. Oxford, Oxford Clinical Communications, 1994.
  25. Stomach – From Mystery to Mechanism. Oxford, Oxford Clinical Communications, 1994.
  26. Sachs G: The parietal cell as a therapeutic target. Scand J Gastroenterol 1986;114(suppl 118):1–10.

    External Resources

  27. Schwarz C: Beitrage zur Pathologie und chirurgischen des penetrierenden Magengeschwüren. Mitt Grenzengeb Med Chir (Jena) 1900;5:821–848.
  28. Schwarz C: Über penetrierende Magen- und Jejunalgeschwüre. Beitr Klin Chir 1910;67:96–128.
  29. Allen A, Garner A: Mucus and bicarbonate secretion in the stomach and their possible role in mucosal protection. Gut 1980;21:249–262.
  30. Teorell T: On the permeability of the stomach mucosa for acid and some other substances. J Gen Physiol 1940;94:308–314.
  31. Code CF, Scholer JF: Barrier offered by gastric mucosa to absorption of sodium. Am J Physiol 1955;183:604–608.
  32. Davenport HW, Warner HA, Code CF: Functional significance of gastric mucosal barrier to sodium. Gastroenterology 1964;47:142–152.
  33. Wallace JL, Granger DN: The cellular and molecular basis of gastric mucosal defence. FASEB J 1996;731–740.
  34. Wallace JL: Prostaglandins, NSAIDs and gastric mucosal protection: Why doesn’t the stomach digest itself? Physiol Rev 2008;88:1547–1565.
  35. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232–235.
  36. Robert A, Schultz RJ, Nezamis JE, Lancaster C: Gastric antisecretory and antiulcer properties of PGE2, 15-methyl-PGE2, 16,16-dimethyl-PGE2. Intravenous, oral and intrajejunal administration. Gastroenterology 1976;70:359–370.
  37. Brzozowski T, Konturek PC, Konturek SJ, Brzozowska I, Pawlik T: Role of prostaglandins in cytoprotection and gastric adaptation. J Physiol Pharmacol 2005;56(suppl 5):33–55.

    External Resources

  38. Tytgat GNJ, Lee A, Graham DY, Dixon MF, Rokkas T: The role of infectious agents in peptic ulcer disease Gastroenterol Intern 1993;6:76.
  39. Dragstedt L: Section of the vagus nerves to the stomach in treatment of peptic ulcer. Ann Surg 1947;126:687–708.
  40. Dragstedt LR: Contributions to the physiology of the stomach. XXXVIII. Gastric juice in duodenal and gastric ulcers. J Am Med Assoc 1917;68:330–333.
  41. Warren JR, Marshall B: Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;i:1273–1275.
  42. Modlin IM, Sachs G: Acid-Related Diseases. Biology and Treatment, ed 2. Constance, Schnetztor, 1998, p 117.
  43. Baron JH: Medical treatment; in Wastell C (ed): Chronic Duodenal Ulcer. London, Butterworths, 1972, pp 117–133.
  44. Modlin IM, Sachs G: Acid-Related Diseases. Biology and Treatment, ed 2. Constance, Schnetztor, 1998, pp 205–210.
  45. Howden CW: Gastric and duodenal ulcers; in Friedman G, Jacobson ED, McCallum RW (eds): Gastrointestinal Pharmacology and Therapeutics. Philadelphia, Lippincott-Raven, 1997, pp 45–54.
  46. Jones DB, Howden CW, Burget DW, Kerr GD, Hunt RH: Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987;28:1120–1127.
  47. Howden CW, Hunt RH: The relationship between and gastric ulcer healing. Aliment Pharmacol Ther 1990;4:25–33.
  48. Nwokolo CU, Smith JT, Gavey C, Sawyer A, Pounder RE: Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990;4(suppl 1):29–46.
  49. Howden CW, Burget DW, Hunt RH: A comparison of different drug classes with respect to rapidity of healing of gastric ulcer. Gastroenterology 1993;104:A105.

    External Resources

  50. Walan A, Bader J-P, Classen M, et al: Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcers. N Engl J Med 1989;320:69–75.
  51. Hunt RH, Cederberg C, Dent J, et al: Optimizing acid suppression for the treatment of acid-related diseases. Dig Dis Sci 1995;40 (suppl):24S–49S.

    External Resources

  52. Freston JW: Omeprazole, hypergastrinemia and gastric carcinoid tumors. Ann Intern Med 1994;121:232–233.
  53. Lanza F, Goff J, Scowcroft C, Jennings D, Greski-Rose P, Lansoprazole Study Group: Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Am J Gastroenterol 1994;89:1191–1200.
  54. Hirschowitz BI: History of acid-peptic diseases from Bismuth to Billroth to Black and back to Bismuth; in Kirsner JB (ed): The Growth of Gastroenterologic Knowledge during the Twentieth Century. Philadelphia, Lea & Febiger, 1994.
  55. Brown Kelly HD: Origins of oesophagoscopy. J R Soc Med 1969;62:781–786.
  56. Schindler R: Lehrbuch und Atlas der Gastroskopie. Munich, Lehmann, 1923.
  57. Hirschowitz BI, Modlin IM: The history of endoscopy: the American perspective; in Classen M, Tytgat GNJ, Lightdale C (eds): Gastroenterological Endoscopy. Stuttgart, Thieme, 2002, pp 2–16.
  58. Hirschowitz BI: Development and application of endoscopy. Gastroenterology 1993;104:337–342.
  59. Elewaut A, Cremer M: The history of gastrointestinal endoscopy – the European perspective; in Classen M, Tytgat GNJ, Lightdale C (eds): Gastroenterological Endoscopy. Stuttgart, Thieme, 2002, pp 17–31.
  60. Kandulski A, Selgrad M, Malfertheiner P: Helicobacter pylori infection: a clinical overview. Dig Liver Dis 2008;40:619–626.
  61. Goodwin RD, Keyes KM, Stein MB, Talley NJ: Peptic ulcer and mental disorders among adults in community: the role of nicotine and alcohol use disorders. Psychosom Med 2009;71:463–468.
  62. Collodel G, Moretti E, Campagna MS, Capitani S, Lenzi C, Figura N: Infection by CagA-positive Helicobacter pylori strains may contribute to alter the sperm quality of men with fertility disorders and increase the systemic levels of TNF-α. Dig Dis Sci 2010;55:94–100.
  63. Sung JJY, Kuipers EJ, El-Serag HB: Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009;29:938–946.
  64. Kang JY, Tinto A, Higham J, Majeed A: Peptic ulceration in general practice in England and Wales 1994–98: period prevalence and drug management. Aliment Pharmacol Ther 2002;16:1067–1074.
  65. Lassen A, Hallas J, Schaffalitzky de Muckadel OB: Complicated and uncomplicated peptic ulcers in Danish county 1993–2002: a population-based cohort study. Am J Gastroenterol 2006;101:945–953.
  66. Post PN, Kuipers EJ, Meijer GA: Declining incidence of peptic ulcer but not of its complications: a nation-wide study in the Netherlands. Aliment Pharmacol Ther 2006;23:1587–1593.
  67. Everhart JE, Ruhl CE: Burden of digestive diseases in the United States. Part I: Overall and upper gastrointestinal diseases. Gastroenterology 2009;136:376–386.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50